EMCURE PHARMACEUTICALS
Back to Balance Sheet
|
EMCURE PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹812 Cr | ₹1,377 Cr | ₹905 Cr | ₹868 Cr | ₹883 Cr |
What is the latest Total Non-Current Liabilities ratio of EMCURE PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹812 Cr |
| Mar2024 | ₹1,377 Cr |
| Mar2023 | ₹905 Cr |
| Mar2022 | ₹868 Cr |
| Mar2021 | ₹883 Cr |
How is Total Non-Current Liabilities of EMCURE PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹812 Cr | -41.04 | |
| Mar2024 | ₹1,377 Cr | 52.24 | |
| Mar2023 | ₹905 Cr | 4.16 | |
| Mar2022 | ₹868 Cr | -1.64 | |
| Mar2021 | ₹883 Cr | - | |
Compare Total Non-Current Liabilities of peers of EMCURE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| EMCURE PHARMACEUTICALS | ₹33,097.0 Cr | 3.2% | 3.2% | 25.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,926.0 Cr | -1.2% | -2.3% | 5.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,062.0 Cr | -1% | -0.9% | -0.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹146,806.0 Cr | -1.3% | 1.4% | 38.1% | Stock Analytics | |
| CIPLA | ₹112,910.0 Cr | -0.1% | 4.8% | -6.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,755.0 Cr | -2.8% | -0.3% | 1.2% | Stock Analytics | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | 3.2% |
3.2% |
25.7% |
| SENSEX | -2% |
-3.8% |
-8.6% |
You may also like the below Video Courses